Immunological abnormalities in cystic fibrosis: chicken or egg?
Cystic fibrosis (CF) is a disease characterised by malabsorption, chronic bronchopulmonary infection, and a high sweat sodium concentration. In 1938 about 80% of patients died within the first year of life' but now many are surviving into adult life,2-4 and are being transferred from the care of the paediatrician to that of the thoracic physician. This increased survival is probably accounted for by improved paediatric care, increased understanding of the importance of efficient postural drainage, and the advent of antibiotics. Patients with CF may develop either pulmonary infection in the neonatal period which persists throughout life or neonatal infection which may respond to treatment only to recur in adolescence. A few patients develop pulmonary infection for the first time in late adolescent or early adult life.
Once bronchopulmonary infection with a given organism is established in a patient with CF it is often impossible to eradicate this organism. While antibiotics may improve the patient's clinical state, respiratory function tests, and chest radiograph for a period, most patients eventually die of overwhelming bronchopulmonary infection by pathogens which appear in the laboratory to be sensitive to the antibiotics with which the patient is being treated. This therefore gives rise to the question as to whether the immune defences of patients with CF may be defective.
In recent years new techniques have been developed to explore both quantitatively and qualitatively the various components of the immune response. These techniques have now been applied to the study of the immune response in cystic fibrosis.
T cell system
Fifty to sixty per cent of peripheral blood lymphocytes are thymus-dependent T cells. They have antigen recognition sites on their surfaces and on stimulation they release lymphokines. These lymphokines have many actions including the activation of macrophages. T cells will transform with phytohaemagglutinin, will help or suppress B 10 years, related to less advanced pulmonary disease, and it has been suggested that initially there may be a failure to recognise antigen when it crosses the gut or respiratory mucosa with a later hyperimmune response. '9 In patients with cystic fibrosis there is a high incidence of severe bronchopulmonary infection without evidence of excessive susceptibility to generalised infections. The 1 skin test reactions to common allergens and A fumigatus together with type 3 responses in skin and serum to A fumigatus have been reported though again it is possible that these findings may be the result of the disease process. Most patients with CF have malabsorption and it is possible that the mucosal defect allows food and bacterial antigens to be absorbed and to sensitise the patient, leading to excess IgE production. Patients with CF are indeed exposed to more bacterial and pharmaceutical antigens than axe fit individuals. It is an unconventional but intriguing explanation that the IgE producing cells may be stimulated as an amplification system to back up the protective role of IgA when the respiratory tract is challenged with many bacterial antigens as it is in these patients with severe lung infection. Such a theory would explain the high prevalence of immediate type 1 skin test responses to common allergens and the various immunological responses to A fumigatus. In classical bronchopulmonary aspergillosis type 1 and type 3 skin tests and serum precipitins are found. However, in CF some patients have precipitins without positive skin test reactions. If the antigen has access through the abnormal mucosal surface of the gut in cystic fibrosis this may cause circulating antibody to be produced without classical skin sensitisation. In allergic bronchopulmonary aspergillosis type 3 reactions to A fumigatus are known to be tissue damaging. It may be that the initial damage to the lung in CF is caused by bacterial infection, but that once infection is established then the lung damage becomes progressively worse as the result of cell-mediated immune reactions to both bacterial and fungal antigens.
These features together with increased levels of circulating immunoglobulins and the finding of autoantibodies in the serum of these patients must stimulate interest in the T cell subpopulations in CF. No work has yet been published on this aspect of the immune response in CF but it needs urgent exploration. If there is some imbalance between suppressor T and helper T cell activity in this disease, this could account for many of the immunological features reported. If this imbalance results in an overactive immune response which is itself causing damage to the already infected lung of the patient with CF, the logical conclusion might be that patients with CF should be treated with steroids or immunosuppressive agents early in life before abnormal immune responses can cause tissue damage. These methods of treatment would however be totally unacceptable without much stronger supporting evidence.
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